## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/37810

A. CLASSIFICATION OF SUBJECT MATTER  **PG(7)						
IPC(7) : A61K 48/00; C12N 15/00, 15/63, 15/74, 5/00 US CL : 514/44; 435/320.1, 325, 455						
According to International Patent Classification (IPC) or to both national classification and IPC						
B. FIELDS SEARCHED						
Minimum documentation searched (classification system followed by classification symbols)						
Minimum doc	sumentation searched (classification system followed by					
U.S. : 514/44; 435/320.1, 325, 455						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
None						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)						
Please See Co	ontinuation Sheet					
C. DOCU	JMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.			
X	SCHOLL S et al Metastatic breast tumour regression following treatment by a gene-		1-2, 4			
	modified vaccinia virus expressing MUC1 and IL-2. J	. Biomed. & Biotech. August 2003,	5 22 24			
Y	Vol. 3, pages 194-201, see entire document		5, 23-24			
		ambination therepy to enhance	1-2, 4,5			
X	AARTS. W.M. et al. Vector-based vaccine/cytokine c induction of immune responses to a self-antigen and a	entitumor activity. Cancer Research.				
Y	2002, Vol. 62, pages 5770-5777, see entire document	intermited man 117.	23-24			
	2002, 401. 02, pagas 5					
Y	ZAJAC P. et al. Phase I/II clinical trial of a nonreplication	ative vaccinia virus expressing multiple	1-2, 4-5, 23-24			
-	HT A-A0201-restricted tumor-associated epitopes and	costimulatory molecules in metastatic				
	melanoma patients. Hum. Gene Ther. 2003, Vol. 14, 1	No. 16, pages 1497-1510, see entire				
	document.					
	COLLY ONE I are all Companies for the development of	recombinant vaccines for the	1			
Х	SCHLOM J. et al. Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer. Breast Canc. Res. Treat. 1996, Vol. 38, pages 27-39, see		***************************************			
Y	entire document.	2, 4-5, 23-24				
•						
Further	documents are listed in the continuation of Box C.	See patent family annex.				
* S	pecial categories of cited documents:	"T" later document published after the inte	emational filing date or priority			
"A" documen	t defining the general state of the art which is not considered to be of	principle or theory underlying the inve	ention			
	particular relevance  "X"  document of particular relevance; the claimed invention cannot be					
"E" earlier ap	plication or patent published on or after the international filing date	considered novel or cannot be considered	red to involve an inventive step			
	t which may throw doubts on priority claim(s) or which is cited to	when the document is taken alone				
establish	the publication date of another citation or other special reason (as	"Y" document of particular relevance; the considered to involve an inventive ste	claimed invention cannot be n when the document is			
specified		combined with one or more other sucl	h documents, such combination			
"O" documen	t referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in th	ic art			
"P" documen	t published prior to the international filing date but later than the	"&" document member of the same patent	family			
priority d	ate claimed		-1			
Date of the a	Date of the actual completion of the international search  Date of mailing of the international search report					
	LE L					
Name and ma	Name and mailing address of the ISA/US  Authorized officer  Authorized officer					
•	Mail Stop PCT, Attn: ISA/US  Anne Marie S. Wehbe					
<del>-</del>	Commissioner for Patents					
P.O. Box 1450 Alexandria, Virginia 22313-1450  Telephone No. 703-308-1235						
Facsimile No. (703) 305-3230						

Form PCT/ISA/210 (second sheet) (January 2004)

## INTERNATIONAL SEARCH REPORT

International application No. PCT/US04/37810

ategory *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	WO 98/04727 (THERION BIOLOGICS CORPORATION) 5 February 1998 (05.02.1998), see	1
 Y	entire document.	2, 4, 5, 23, 24
I		
		•
! !		
		•
:		

INTERNATIONAL SEARCH REPORT	PCT/US04/37810
	•
	·
Continuation of B. FIELDS SEARCHED Item 3: DIALOG-medicine database; BRS/EAST-USPatful, EPO, JPO, Derwint, PB-Pubs search terms: vaccinia, poxvirus, nyvac, alvac, mva, wyeth, CEA, mucin, her-2/neu,	muc-1, gm-csf, b7, tricom

Form PCT/ISA/210 (extra sheet) (January 2004)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/37810

Box No. II	Observations where certain claims were found unsearchable (Continuation of item 2 of inst sheet)			
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:			
2.	Claims Nos.: 2 in part because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Claim 2 is a multiple dependent claim that depends in the alternative on itself. As such, the claim has only been considered to the extent that it depends on claim 1.			
3.	Claims Nos.: 3 and 6-22 because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box No. II	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)			
This Internat	ional Searching Authority found multiple inventions in this international application, as follows:			
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite			
3.	payment of any additional fee.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:			
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:			
D				
Remark on	No protest accompanied the payment of additional search fees.			